Check out our publications

Culturing and expansion of  “clinical grade” precursors cells from the fetal human central nervous system.
Gelati M, Profico D, Projetti-Pensi M, Muzi G, Sgaravizzi G, Vescovi AL. “Culturing and expansion of “clinical grade” precursors cells from the fetal human central nervous system.” Methods Mol Biol. 2013;1059:65-77. doi: 10.1007/978-1-62703-574-3_6.
Vaccinia virus expressing bone morphogenetic protein-4 in novel glioblastoma orthotopic models facilitates enhanced tumor regression and long-term survival.”
Duggal R, Geissinger U, Zhang Q, Aguilar J, Chen NG, Binda E, Vescovi AL, Szalay AA. “Vaccinia virus expressing bone morphogenetic protein-4 in novel glioblastoma orthotopic models facilitates enhanced tumor regression and long-term survival.” J Transl Med. 2013 Jun 24;11(1):155. [Epub ahead of print]
Stemness underpinning all steps of human colorectal cancer defines the core of effective therapeutic strategies. EBioMedicine, 44, 346-360.
Visioli, A., F. Giani, N. Trivieri, R. Pracella, E. Miccinilli, M. G. Cariglia, O. Palumbo, A. Arleo, F. Dezi, M. Copetti, L. Cajola, S. Restelli, V. Papa, A. Sciuto, T. P. Latiano, M. Carella, D. Amadori, G. Gallerani, R. Ricci, S. Alfieri, G. Pesole, A. L. Vescovi & E. Binda (2019)
The EphA2 Receptor Drives Self-Renewal and Tumorigenicity in Stem-Like Tumor-Propagating Cells from Human Glioblastomas.
IF 38.58
Elena Binda, Alberto Visioli, Fabrizio Giani, Giuseppe Lamorte, Massimiliano Copetti, Ken L. Pitter, Jason T. Huse, Laura Cajola, Nadia Zanetti, Francesco DiMeco, Lidia De Filippis, Annunziato Mangiola, Giulio Maira, Carmelo Anile, Pasquale De Bonis, Brent A. Reynolds, Elena B. Pasquale and Angelo L. Vescovi. The EphA2 Receptor Drives Self-Renewal and Tumorigenicity in Stem-Like Tumor-Propagating Cells from Human Glioblastomas. Cancer Cell 2012 Dec 11;22(6):765-80.
Heterogeneity of cancer-initiating cells within glioblastoma.
Binda E, Visioli A, Reynolds B, Vescovi AL. Heterogeneity of cancer-initiating cells within glioblastoma. Front Biosci (Schol Ed). 2012 Jun 1;4:1235-48.
Wnt5a Drives an Invasive Phenotype in Human Glioblastoma Stem-like Cells. Cancer Res, 77, 996-1007.
IF 11.2
Binda, E., A. Visioli, F. Giani, N. Trivieri, O. Palumbo, S. Restelli, F. Dezi, T. Mazza, C. Fusilli, F. Legnani, M. Carella, F. Di Meco, R. Duggal & A. L. Vescovi (2017)
CD90 is identified as a marker for cancer stem cells in primary high-grade gliomas using tissue microarrays
He J, Liu Y, Zhu T, Zhu J, Dimeco F, Vescovi AL, Heth JA, Muraszko KM, Fan X, Lubman DM. CD90 is identified as a marker for cancer stem cells in primary high-grade gliomas using tissue microarrays. Mol Cell Proteomics. 2011 Dec 27.
Glioma stem cells: turpis omen in nomen? (The evil in the name?)
Binda E, Reynolds BA, Vescovi AL.J Intern Med. 2014 Jul;276(1):25-40. doi: 10.1111/joim.12254.PMID: 24708237 Review.
Drug Delivery in an Orthotopic Tumor Stem Cell-Based Model of Human Glioblastoma.
Binda E, Visioli A, Trivieri N, Vescovi AL.Methods Mol Biol. 2019;1869:197-205. doi: 10.1007/978-1-4939-8805-1_17.PMID: 30324525
Results from Phase I Clinical Trial with Intraspinal Injection of Neural Stem Cells in Amyotrophic Lateral Sclerosis: A Long-Tern Outcome.
Mazzini L, Gelati M, Profico DC, Soraru G, Ferrari D, Copetti M, Muzi G, Ricciolini C, Carletti S, Giorgi C, Spera C, Frondizi D, Masiero S, Stecco A, Cisari C, Bersano E, De Marchi F, Sarnelli MF, Querin G, Cantello R, Petruzzelli F, Maglione A, Zalfa C, Binda E, Visioli A, Trombetta D, Torres B, Bernardini L, Gaiani A, Massara M, Paolucci S, Boulis NM, Vescovi AL. Stem Cells Trans Med. 2019; 8(9):887-897. PMID: 30324525
Different states of stemness of glioblastoma stem cells sustain glioblastoma subtypes indicating novel clinical biomarkers and high-efficacy customized therapies. J Exp Clin Cancer Res, 42, 244.
IF 11.2
Visioli, A., N. Trivieri, G. Mencarelli, F. Giani, M. Copetti, O. Palumbo, R. Pracella, M. G. Cariglia, C. Barile, L. Mischitelli, A. A. Soriano, P. Palumbo, F. Legnani, F. DiMeco, L. Gorgoglione, G. Pesole, A. L. Vescovi & E. Binda (2023)
Local delivery of hrBMP4 as an anticancer therapy in patients with recurrent glioblastoma: a first-in-human phase 1 dose escalation trial. Mol Cancer, 22,129.
IF 44.1
Bos E.M., E. Binda, I.S.C. Verploegh, E. Wembacher, D. Hoefnagel, R.K. Balvers, A.L. Korporaal, A. Conidi, E.A.H. Warnert, N. Trivieri, A. Visioli, P. Zaccarini, L.Caiola, R. van Wijck, P. van der Spek, D. Huylebroeck, S. Leenstra, M.L.M. Lamfers, Z. Ram, M. Westphal, D. Noske, F. Legnani, F. DiMeco, A.L. Vescovi & C.M.F. Dirven (2023)
Growth factor independence underpins a paroxysmal, aggressive Wnt5ahigh/EphA2low phenotype in glioblastoma stem cells, conducive to experimental combinatorial therapy. J Exp Clin Cancer Res, 41, 139. *Co-Author.
IF 11.3
Trivieri, N. *, Visioli A. *, Mencarelli G., Cariglia M.G., Marongiu L., Pracella R., Giani F., Soriano A.A., Barile C., Copetti M., Palumbo O., Legnani F., DiMeco F., Gorgoglione L., Vescovi A.L., Binda E. (2022)
BRAF V600E mutation impinges on gut microbial markers defining novel biomarkers for serrated colorectal cancer effective therapies. J Exp Clin Cancer Res, 39, 285.
IF 11.5
Trivieri, N., R. Pracella, M. G. Cariglia, C. Panebianco, P. Parrella, A. Visioli, F. Giani, A. A. Soriano, C. Barile, G. Canistro, T. P. Latiano, L. Dimitri, F. Bazzocchi, D. Cassano, A. L. Vescovi, V. Pazienza & E. Binda (2020)

Download the list of all publications